Cargando…
Differential Effect of SARS-CoV-2 Spike Glycoprotein 1 on Human Bronchial and Alveolar Lung Mucosa Models: Implications for Pathogenicity
Background: The SARS-CoV-2 spike protein mediates attachment of the virus to the host cell receptor and fusion between the virus and the cell membrane. The S1 subunit of the spike glycoprotein (S1 protein) contains the angiotensin converting enzyme 2 (ACE2) receptor binding domain. The SARS-CoV-2 va...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708014/ https://www.ncbi.nlm.nih.gov/pubmed/34960806 http://dx.doi.org/10.3390/v13122537 |
_version_ | 1784622578836439040 |
---|---|
author | Rahman, Mizanur Irmler, Martin Keshavan, Sandeep Introna, Micol Beckers, Johannes Palmberg, Lena Johanson, Gunnar Ganguly, Koustav Upadhyay, Swapna |
author_facet | Rahman, Mizanur Irmler, Martin Keshavan, Sandeep Introna, Micol Beckers, Johannes Palmberg, Lena Johanson, Gunnar Ganguly, Koustav Upadhyay, Swapna |
author_sort | Rahman, Mizanur |
collection | PubMed |
description | Background: The SARS-CoV-2 spike protein mediates attachment of the virus to the host cell receptor and fusion between the virus and the cell membrane. The S1 subunit of the spike glycoprotein (S1 protein) contains the angiotensin converting enzyme 2 (ACE2) receptor binding domain. The SARS-CoV-2 variants of concern contain mutations in the S1 subunit. The spike protein is the primary target of neutralizing antibodies generated following infection, and constitutes the viral component of mRNA-based COVID-19 vaccines. Methods: Therefore, in this work we assessed the effect of exposure (24 h) to 10 nM SARS-CoV-2 recombinant S1 protein on physiologically relevant human bronchial (bro) and alveolar (alv) lung mucosa models cultured at air–liquid interface (ALI) (n = 6 per exposure condition). Corresponding sham exposed samples served as a control. The bro-ALI model was developed using primary bronchial epithelial cells and the alv-ALI model using representative type II pneumocytes (NCI-H441). Results: Exposure to S1 protein induced the surface expression of ACE2, toll like receptor (TLR) 2, and TLR4 in both bro-ALI and alv-ALI models. Transcript expression analysis identified 117 (bro-ALI) and 97 (alv-ALI) differentially regulated genes (p ≤ 0.01). Pathway analysis revealed enrichment of canonical pathways such as interferon (IFN) signaling, influenza, coronavirus, and anti-viral response in the bro-ALI. Secreted levels of interleukin (IL) 4 and IL12 were significantly (p < 0.05) increased, whereas IL6 decreased in the bro-ALI. In the case of alv-ALI, enriched terms involving p53, APRIL (a proliferation-inducing ligand) tight junction, integrin kinase, and IL1 signaling were identified. These terms are associated with lung fibrosis. Further, significantly (p < 0.05) increased levels of secreted pro-inflammatory cytokines IFNγ, IL1ꞵ, IL2, IL4, IL6, IL8, IL10, IL13, and tumor necrosis factor alpha were detected in alv-ALI, whereas IL12 was decreased. Altered levels of these cytokines are also associated with lung fibrotic response. Conclusions: In conclusion, we observed a typical anti-viral response in the bronchial model and a pro-fibrotic response in the alveolar model. The bro-ALI and alv-ALI models may serve as an easy and robust platform for assessing the pathogenicity of SARS-CoV-2 variants of concern at different lung regions. |
format | Online Article Text |
id | pubmed-8708014 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87080142021-12-25 Differential Effect of SARS-CoV-2 Spike Glycoprotein 1 on Human Bronchial and Alveolar Lung Mucosa Models: Implications for Pathogenicity Rahman, Mizanur Irmler, Martin Keshavan, Sandeep Introna, Micol Beckers, Johannes Palmberg, Lena Johanson, Gunnar Ganguly, Koustav Upadhyay, Swapna Viruses Article Background: The SARS-CoV-2 spike protein mediates attachment of the virus to the host cell receptor and fusion between the virus and the cell membrane. The S1 subunit of the spike glycoprotein (S1 protein) contains the angiotensin converting enzyme 2 (ACE2) receptor binding domain. The SARS-CoV-2 variants of concern contain mutations in the S1 subunit. The spike protein is the primary target of neutralizing antibodies generated following infection, and constitutes the viral component of mRNA-based COVID-19 vaccines. Methods: Therefore, in this work we assessed the effect of exposure (24 h) to 10 nM SARS-CoV-2 recombinant S1 protein on physiologically relevant human bronchial (bro) and alveolar (alv) lung mucosa models cultured at air–liquid interface (ALI) (n = 6 per exposure condition). Corresponding sham exposed samples served as a control. The bro-ALI model was developed using primary bronchial epithelial cells and the alv-ALI model using representative type II pneumocytes (NCI-H441). Results: Exposure to S1 protein induced the surface expression of ACE2, toll like receptor (TLR) 2, and TLR4 in both bro-ALI and alv-ALI models. Transcript expression analysis identified 117 (bro-ALI) and 97 (alv-ALI) differentially regulated genes (p ≤ 0.01). Pathway analysis revealed enrichment of canonical pathways such as interferon (IFN) signaling, influenza, coronavirus, and anti-viral response in the bro-ALI. Secreted levels of interleukin (IL) 4 and IL12 were significantly (p < 0.05) increased, whereas IL6 decreased in the bro-ALI. In the case of alv-ALI, enriched terms involving p53, APRIL (a proliferation-inducing ligand) tight junction, integrin kinase, and IL1 signaling were identified. These terms are associated with lung fibrosis. Further, significantly (p < 0.05) increased levels of secreted pro-inflammatory cytokines IFNγ, IL1ꞵ, IL2, IL4, IL6, IL8, IL10, IL13, and tumor necrosis factor alpha were detected in alv-ALI, whereas IL12 was decreased. Altered levels of these cytokines are also associated with lung fibrotic response. Conclusions: In conclusion, we observed a typical anti-viral response in the bronchial model and a pro-fibrotic response in the alveolar model. The bro-ALI and alv-ALI models may serve as an easy and robust platform for assessing the pathogenicity of SARS-CoV-2 variants of concern at different lung regions. MDPI 2021-12-17 /pmc/articles/PMC8708014/ /pubmed/34960806 http://dx.doi.org/10.3390/v13122537 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rahman, Mizanur Irmler, Martin Keshavan, Sandeep Introna, Micol Beckers, Johannes Palmberg, Lena Johanson, Gunnar Ganguly, Koustav Upadhyay, Swapna Differential Effect of SARS-CoV-2 Spike Glycoprotein 1 on Human Bronchial and Alveolar Lung Mucosa Models: Implications for Pathogenicity |
title | Differential Effect of SARS-CoV-2 Spike Glycoprotein 1 on Human Bronchial and Alveolar Lung Mucosa Models: Implications for Pathogenicity |
title_full | Differential Effect of SARS-CoV-2 Spike Glycoprotein 1 on Human Bronchial and Alveolar Lung Mucosa Models: Implications for Pathogenicity |
title_fullStr | Differential Effect of SARS-CoV-2 Spike Glycoprotein 1 on Human Bronchial and Alveolar Lung Mucosa Models: Implications for Pathogenicity |
title_full_unstemmed | Differential Effect of SARS-CoV-2 Spike Glycoprotein 1 on Human Bronchial and Alveolar Lung Mucosa Models: Implications for Pathogenicity |
title_short | Differential Effect of SARS-CoV-2 Spike Glycoprotein 1 on Human Bronchial and Alveolar Lung Mucosa Models: Implications for Pathogenicity |
title_sort | differential effect of sars-cov-2 spike glycoprotein 1 on human bronchial and alveolar lung mucosa models: implications for pathogenicity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708014/ https://www.ncbi.nlm.nih.gov/pubmed/34960806 http://dx.doi.org/10.3390/v13122537 |
work_keys_str_mv | AT rahmanmizanur differentialeffectofsarscov2spikeglycoprotein1onhumanbronchialandalveolarlungmucosamodelsimplicationsforpathogenicity AT irmlermartin differentialeffectofsarscov2spikeglycoprotein1onhumanbronchialandalveolarlungmucosamodelsimplicationsforpathogenicity AT keshavansandeep differentialeffectofsarscov2spikeglycoprotein1onhumanbronchialandalveolarlungmucosamodelsimplicationsforpathogenicity AT intronamicol differentialeffectofsarscov2spikeglycoprotein1onhumanbronchialandalveolarlungmucosamodelsimplicationsforpathogenicity AT beckersjohannes differentialeffectofsarscov2spikeglycoprotein1onhumanbronchialandalveolarlungmucosamodelsimplicationsforpathogenicity AT palmberglena differentialeffectofsarscov2spikeglycoprotein1onhumanbronchialandalveolarlungmucosamodelsimplicationsforpathogenicity AT johansongunnar differentialeffectofsarscov2spikeglycoprotein1onhumanbronchialandalveolarlungmucosamodelsimplicationsforpathogenicity AT gangulykoustav differentialeffectofsarscov2spikeglycoprotein1onhumanbronchialandalveolarlungmucosamodelsimplicationsforpathogenicity AT upadhyayswapna differentialeffectofsarscov2spikeglycoprotein1onhumanbronchialandalveolarlungmucosamodelsimplicationsforpathogenicity |